Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, an increase of 24.0% from the December 15th total of 9,589,100 shares. Approximately 11.7% of the company’s shares are short sold. Based on an average daily volume of 3,196,474 shares, the short-interest ratio is currently 3.7 days. Based on an average daily volume of 3,196,474 shares, the short-interest ratio is currently 3.7 days. Approximately 11.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Fractyl Health

Hedge funds have recently made changes to their positions in the company. Woodline Partners LP grew its stake in shares of Fractyl Health by 47.2% during the first quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after buying an additional 165,786 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Fractyl Health in the 2nd quarter worth approximately $181,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Fractyl Health in the 2nd quarter worth $26,000. Qube Research & Technologies Ltd purchased a new position in shares of Fractyl Health in the 2nd quarter valued at approximately $129,000. Finally, General Catalyst Group Management LLC purchased a new stake in Fractyl Health during the 2nd quarter valued at about $7,912,000.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Fractyl Health Stock Performance

Shares of GUTS stock traded down $0.06 during mid-day trading on Monday, hitting $1.91. The company’s stock had a trading volume of 2,523,545 shares, compared to its average volume of 2,453,125. The stock has a market cap of $261.75 million, a price-to-earnings ratio of -0.83 and a beta of 1.62. Fractyl Health has a 52-week low of $0.83 and a 52-week high of $3.03. The business has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.51.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Equities research analysts predict that Fractyl Health will post -1.61 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.